Book Value per Share: Advanced Biomed (ADVB)

Public company logo of Advanced Biomed Inc (ADVB)

Advanced Biomed Inc (ADVB) focuses on developing precision tumor micro-screening systems, planning to monetize microfluidic platforms for rapid therapy selection. The book value per share confirms the R&D stage, where the metric stands at 0.23. However, expansion is complicated by a fierce battle for physician adoption and pressure from accessible liquid biopsy methods.

Advanced Biomed Corp (ADVB) - Accounting Value per Share from 03/07/2025 to 10/26/2026
Manufactured product of Advanced Biomed Inc.

Book value per share reflects the accounting value of net assets, allowing an investor to compare the current market price with the real value of the company's capital in retrospect. By analyzing the net assets per common share, one can assess the extent to which investments in early cancer detection systems from Advanced Biomed Inc. (ADVB) are being capitalized, creating a foundation for the long-term financial stability of the business.

Competitor analysis for Advanced Biomed Inc

ONC - Accounting Value per Share|HALO - Net Assets per Single Share|Revolution Medicines (RVMD) - Book Value per Share|ascentage.com (AAPG) - Net Assets per Single Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share OS Therapies, Inc.|Book Value per Share RADX|Book Value per Share artivabio.com (ARTV)|ANL - Book Value per Share|VERU - Equity per Share|TPST - Accounting Value per Share|XLO - Net Assets per Single Share|RENB: Book Value per Share|MURA (Mural Oncology) - Book Value per Share|Net Assets per Single Share Kairos Pharma Limited (KAPA)|Equity per Share OnKure|Book Value per Share GDTC (CytoMed Therapeutics)|Accounting Value per Share curis.com (CRIS)|APLM: Book Value per Share|Net Asset Value per Share tharimmune.com THAR|Genprex (GNPX) - Book Value per Share|Calidi Biotherapeutics (CLDI) - Equity per Share|Accounting Value per Share Sunshine Biopharma, Inc. SBFM|Xenetic Biosciences, Inc. (XBIO) - Accounting Value of a Share|Book Value per Share Salarius Pharmaceuticals|Net Assets per Single Share purple-biotech.com|AONC (American Oncology Network) - Book Value per Share|Net Assets per Share BGNE (BeiGene Ltd.)|CKPT: Net Assets per Single Share|elevationoncology.com - Net Asset Value per Share|ICAD: Net Assets per Single Share|IKNA - Accounting Value per Share|Book Value per Share NTBL|Viracta Therapeutics, Inc. (VIRX) - Net Asset Value per Share|Book Value per Share MorphoSys Corp (MOR)|Equity per Share NAYA Biosciences Corp (NAYA)|Ascentage Pharma Group (AAPGV) - Accounting Value per Share